| page | |
| OBITUARY |
| 182 | Obituary for Prof Shiro Kira, Emeritus Professor, Juntendo University and Jichi Medical College
|
| EDITORIALS |
| 184 | Fluticasone furoate: CAPTAIN of fluticasones in type 2 inflammatory asthma
|
| 187 | Piecing together the bigger picture: Idiopathic pulmonary fibrosis in Australia and beyond
|
| 190 | Friend or foe? Corticosteroids in sarcoidosis
|
| 192 | Progressive fibrosing hypersensitivity pneumonitis: Why wait?
|
| SYSTEMATIC REVIEW |
| 194 | Quantitative comparison of dose–effect and time–course of fluticasone furoate and fluticasone propionate in adult and adolescent patients with persistent asthma: A systematic review and meta-analysis
|
| ORIGINAL ARTICLES |
| Interstitial Lung Disease |
| 202 | Short-term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis
Claudio Macaluso, Cristina Boccabella, Maria Kokosi, Nishanth Sivarasan, Vasilis Kouranos, Peter M George, George Margaritopoulos, Philip L Molyneaux, Felix Chua, Toby M Maher, Gisli R Jenkins, Andrew G Nicholson, Sujal R Desai, Anand Devaraj, Athol U Wells, Elisabetta A Renzoni, Carmel J W Stock
10.1111/resp.14204
A proportion of patients with fibrotic hypersensitivity pneumonitis have high mortality, and short-term predictors of poorer survival are needed. Declines from baseline at 1 year in forced vital capacity (FVC) ≥ 10% and diffusion capacity of the lung for carbon monoxide (DLCO) ≥15%, but also marginal declines in FVC ≥ 5% and DLCO ≥ 10%, are predictive of increased mortality. |
| 209 |
Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia
Ingrid A Cox, Petr Otahal, Barbara de Graaff, Tamera J Corte, Yuben Moodley, Chris Zappala, Ian Glaspole, Peter Hopkins, Sacha Macansh, E Haydn Walters, Andrew J Palmer
10.1111/resp.14194
Our study provides the first estimates for incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia. Overall crude and age-standardized estimates for mortality were 5.9 and 6.3 per 100,000 population; incidence, 10.4 and 11.2 per 100,000 population; and prevalence, 32.6 and 35.1 per 100,000 population. |
| 217 | Sarcoidosis-related mortality and the impact of corticosteroid treatment: A population-based cohort study
Melina Gade Sikjær, Ole Hilberg, Rikke Ibsen, Anders Løkke
10.1111/resp.14202
We evaluated mortality in a cohort of 9795 sarcoidosis cases during an 18-year follow-up period (2001–2018). Mortality was significantly increased in sarcoidosis cases compared with the background population. Corticosteroid treatment was associated with particularly high mortality rates. |
| Rare Lung Disease |
| 226 | Interstitial lung diseases associated with mutations of poly(A)-specific ribonuclease: A multicentre retrospective study
Quentin Philippot, Caroline Kannengiesser, Marie Pierre Debray, Clément Gauvain, Ibrahima Ba, Margherita Vieri, Anne Gondouin, Jean-Marc Naccache, Martine Reynaud-Gaubert, Yurdagul Uzunhan, Benjamin Bondue, Dominique Israël-Biet, Philippe Dieudé, Cécile Fourrage, Elodie Lainey, Effrosyne Manali, Spyros Papiris, Lidwine Wemeau, Sandrine Hirschi, Hervé Mal, Hilario Nunes, Frédéric Schlemmer, Elodie Blanchard, Fabian Beier, Vincent Cottin, Bruno Crestani, Raphaël Borie, The OrphaLung Network
10.1111/resp.14195
The pulmonary phenotypes of 31 patients with interstitial lung disease (ILD) and heterozygous poly(A)-specific ribonuclease (PARN) mutations in this cohort were heterogeneous, but idiopathic pulmonary fibrosis was the most frequent diagnosis. Haematological and hepatic features were less frequent than in patients affected with telomerase reverse transcriptase (TERT)- or telomerase RNA component (TERC)-associated ILDs. |
| LETTERS FROM ASIA-PACIFIC AND BEYOND |
| 236 |
Opening opportunities for women in respiratory medicine: Letter from Korea
Young Ae Kang PhD, Ji Ye Jung PhD
10.1111/resp.14212
Special Series: Leading Women in Respiratory Medicine
Series Editors: Natasha Smallwood and Fanny Wai San Ko |
| 239 |
Advancing leaders and leadership: New Zealand women in respiratory medicine
Elaine Yap MBChB, FRACP, Sarah Mooney DHSc, MSc, BSc (Hons) Physiotherapy
10.1111/resp.14211
Special Series: Leading Women in Respiratory Medicine.
Series Editors: Natasha Smallwood and Fanny Wai San Ko |
| 242 | Letter from Egypt
Ramy Mohamed Ghazy DrPH, Sarah Hamed N Taha PhD, Yasir Ahmed Mohammed Elhadi BPharm
10.1111/resp.14205 |
| FORUM AND DEBATE |
| Correspondence |
| 245 | Usage of IL-6 antagonists in COVID-19: A challenge in children
Man Man Niu MD, Guo Zhen Fan MD, Rui Xue Li MD, Qi Jiang MD, Peng Hu MD, PhD
10.1111/resp.14207 |
| 246 | Reply
Christos Kyriakopoulos MD, PhD, Athena Gogali MD, PhD, Georgios Ntritsos PhD, Haralampos Milionis MD, PhD, Evangelos Evangelou PhD, Konstantinos Kostikas MD, PhD
10.1111/resp.14206 |
